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INTRODUCTION: 
The poorly soluble drug having dissolution rate too slow 
therefore uptake cannot be completed within the time at 
absorption site. If it remains in GIT for longer period may 
lead to decomposition of drug. There are two parameters 
useful for identifying poorly soluble drugs. One is its 
aqueous solubility should be less than 100ug/ml and 
another is dose: solubility ratio. Dose: solubility ratio can 
be defined as volume of gastrointestinal fluids necessary to 
dissolve the administered dose. 
1
 
The liquisolid technique as described by Spireas is a novel 
concept, where a liquid may be transformed into a free 
flowing, readily compressible and apparently dry powder 
by simple physical blending with selected carrier and 
coating material. The liquid portion, which can be a liquid 
drug, a drug suspension or a drug solution in suitable non-
volatile liquid vehicles, is included into the porous carrier 
material. Inert, preferably water-miscible organic solvent 
systems with high boiling point such as liquid 
polyethylene glycols, propylene glycol, or glycerine are 
most excellent fitting as liquid vehicles. As the carrier is 
saturated with liquid, a liquid layer is formed on the 
particle surface which is instantlyadsorbed by the fine 
coating particles.
2 
Solid dispersions consist of one or more active ingredients 
dispersed in a readily soluble solid hydrophilic matrix 
prepared by a melting (fusion) or solvent method
3
. With 
the melting method the drug is added to the molten carrier 
and the mixture is stirred until a homogenous melt is 
obtained. With the solvent method drug and carrier are 
dissolved in small amounts of solvent with final solvent 
evaporation. The higher release rates of solid dispersions 
may be ascribed to a number of factors which include 
formation of the amorphous form of the drug, reduction of 
particle size to nearly the molecular level, improved 
wetting properties and solubilisation of the drug by the 
carrier. The advantages of this methodology are the 
molecular dispersion of the drug within the hydrophilic 
carrier and the comparably high drug stability. However, 
for the preparation of solid dispersions usually special 
equipment is needed such as a spray dryer or a fluid bed 
apparatus.
4-9 
Liqisolid compact: 
Liquisolid technique is a new and promising method that 
can change the dissolution rate of drugs. It has been used 
to enhance dissolution rate of poorly water-soluble drugs. 
For poorly soluble (Class II) drugs and class (Class IV) the 
rate of oral absorption is often controlled by the dissolution 
rate in the gastrointestinal tract. The new ‘liquisolid’’ 
technique may be applied to formulate liquid medications 
(i.e., oily liquid drugs and solutions, suspensions or 
emulsions of water-insoluble solid drugs carried in 
nonvolatile liquid vehicles) into powders suitable for 
tableting or encapsulation. Since, the liquisolid tablets 
contain a solution of the drug in suitable solvent; the drug 
surface available for dissolution is tremendously increased. 
Due to significantly increased wetting properties and 
surface area of drug available for dissolution, liquisolid 
compacts of waterinsoluble substances may be expected to 
display enhanced drug release characteristics and, 
consequently, improved oral bioavailability. 
ABSTRACT: 
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Drugs that can be incorporated into liquisolid systems: 
Antihistaminic: chlorpheniramine 
Antiarrthymic: digoxin, digitoxin 
Antihypertensive: nifedipine 
Antilipidemics: clofibrate, gemfibrozil 
Antiepileptic: Carbamazepine, valproic acid.  
Chemotherapeutic agent: etoposide.  
Diuretics: Hydrochlorothiazide, methylchlorthiazide, 
polythiazide, spironolactone.  
Glucocorticoids: prednisolone, hydrocortisone, prednisone.  
NSAIDS: piroxicam, indomethacin, ibuprofen.  
Water-insoluble vitamins: vitamin A, D, E, and K  
Advantages: 
 Huge number of Bio-Pharmaceutical classification 
class II drugs with high permeability, slightly or very 
slightly water soluble and practically insoluble liquids 
and solid drugs can be formulated into liquisolid 
systems. 
 Improvement of bioavailability of an 
orallyadministered water insoluble drugs is achieved. 
 This principle governs or administers the 
mechanismof drug delivery from liquisolid systems of 
powdereddrug solutions and it is mainly responsible 
for theimproved dissolution profiles exhibited by 
thispreparations. 
 In this technique, production cost is low compared 
tosoft gelatin capsules. 
 Drug is formulated in a tablet form or 
encapsulateddosage form and is held in solubilized 
liquid state,which confers developed or improved drug 
wettingproperties thereby improving drug 
dissolutionprofiles. 
 Greater drug surface area is exposed to the 
dissolutionmedium.This liquisolid system is 
specifically for powderedliquid medications. 
  Capability of industrial production is also possible. 
 Enhanced bioavailability can be obtained as compared 
to conventional tablets. 
 Differentiate the dosage form by admixture of 
colorinto liquid vehicle. 
Limitations
10
: 
 Formulation of high dose lipophilic drugs theliquisolid 
tablet is one of the limitations of thistechnique. 
 This techniques is not applicable forhigh dose 
insoluble drug. 
 Mathematical calculations require. 
Advantages of liqisolid tablets over convention tablets: 
 Liquisolid systems are low cost formulations than 
soft gelatin capsules.  
 Production of them is similar to that of conventional 
tablets.  
 Drug release can be modified using suitable 
formulation ingredients.  
 Drug can be molecularly dispersed in the 
formulation.  
 Capability of industrial production is also possible.  
 Enhanced bioavailability can be obtained as 
compared to conventional tablets.  
 Omit the process approaches like nanonisation, 
micronization techniques.  
 Differentiate the dosage form by admixture of colour 
into liquid vehicle.  
 To minimize excipients in formulation compare with 
other formulations like solid dispersions.  
Theory of liquid solid systems: 
A powder can retain only limited amounts of liquid 
whilemaintaining acceptable flow and compression 
properties. Tocalculate the required amounts of powder 
excipients (carrierand coating materials) a mathematical 
approach for theformulation of liqui-solid systems has 
been developed bySpirea,. This approach is based on the 
flowable (Ф-value) and compressible (Ψ-number) liquid 
retentionpotential introducing constants for each 
powder/liquidcombination. 
The Ф-value of a powder represents the maximum 
amountof a given non-volatile liquid that can be retained 
inside itsbulk [w/w] while maintaining an acceptable 
flowability. Theflowability may be determined from the 
powder flow or bymeasurement of the angle of repose. The 
Ψ-number of apowder is defined as the maximum amount 
of liquid thepowder can retain inside its bulk [w/w] while 
maintainingacceptable compactability resulting in 
compacts of sufficienthardness with no liquid leaking out 
during compression.
11, 12,
 
Depending on the excipient ratio (R) of the powder 
substratean acceptably flowing and compressible liqui-
solid systemcan be obtained only if a maximum liquid load 
on the carriermaterial is not exceeded. This liquid/carrier 
ratio is termed“liquid load factor Lf [w/w] and is defined 
as the weightratio of the liquid formulation (W) and the 
carrier material(Q) in the system: 
Lf = W/Q------ (1) 
‘R’ represents the ratio between the weights of the 
carrier(Q) and the coating (q) material present in the 
formulation: 
R =Q/q------ (2) 
The liquid load factor that ensures acceptable 
flowability(Lf ) can be determined by: 
Lf =Φ+ φ. (1/R) ----- (3) 
Where Φ and φ are the Ф-values of the carrier and 
coatingmaterial, respectively. Similarly, the liquid load 
factor forproduction of liqui-solid systems with 
acceptablecompactability (ΨLf) can be determined by: 
Ψ Lf= Ψ + ψ.(1/R ------- (4) 
Where Ψ and ψ are the Ψ-numbers of the carrier and 
coatingmaterial, respectively. 
Classification: 
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 Based on the type of liquidmedication contained 
therein, liquisolidsystems may be classified into 
threesubgroups: 
 Powdered drug solutions 
 Powdered drug suspensions 
 Powdered liquid drugs 
The first two may be produced from theconversion of drug 
solutions or (e.g.prednisolone solution in propylene glycol) 
ordrug suspensions (e.g. gemfibrozilsuspension in 
Polysorbate 80), and thelatter from the formulation of 
liquid drugs(e.g. clofibrate, valproic acid, liquid 
vitamins,etc.), into liquisolid systems. 
 Based on the formulation techniqueused, liquisolid 
systems may be classifiedinto two categories, namely, 
 Liquisolid compacts 
 Liquisolid microsystems 
Liquisolid compacts are prepared using thepreviously 
outlined method to producetablets or capsules, whereas the 
liquisolidmicrosystems are based on a new conceptwhich 
to produce an acceptably flowingadmixture for 
encapsulations.
13
 
Mechanism of enhanced drug release: 
From liquid solid systems: 
Several mechanisms of enhanced drug release have 
beenpostulated for liqui-solid systems. The three main 
suggestedmechanisms include an increased surface area of 
drugavailable for release, an increased aqueous solubility 
of thedrug, and an improved wettability of the drug 
particles. 
Formation of a complex between the drug and excipients 
orany changes in crystallinity of the drug could be ruled 
outusing DSC and XRPD measurements. 
a. Increased Drug Surface Area 
If the drug within the liqui-solid system is 
completelydissolved in the liquid vehicle it is located in 
the powdersubstrate still in a solubilized, molecularly 
dispersed state.Therefore, the surface area of drug 
available for release ismuch greater than that of drug 
particles within directlycompressed tablets
12
. 
b. Increased Aqueous Solubility of the Drug 
In addition to the first mechanism of drug 
releaseenhancement it is expected thatCs, the solubility of 
the drug,might be increased with liqui-solid systems. In 
fact, therelatively small amount of liquid vehicle in a liqui-
solidcompact is not sufficient to increase the overall 
solubility ofthe drug in the aqueous dissolution medium. 
However, at thesolid/liquid interface between an individual 
liqui-solidprimary particle and the release medium it is 
possible that inthis microenvironment the amount of liquid 
vehiclediffusing out of a single liqui-solid particle together 
with thedrug molecules might be sufficient to increase the 
aqueoussolubility of the drug if the liquid vehicle acts as a 
cosolvent
12
. 
c. Improved Wetting Properties 
Due to the fact that the liquid vehicle can either act 
assurface active agent or has a low surface tension, wetting 
ofthe liqui-solid primary particles is improved.Wettability 
of these systems has been demonstrated bymeasurement of 
contact angles and water rising times.
14
 
Many poorly soluble drugs have been formulated as 
liquisolidsystems showing enhanced drug release. 
Differentliquid vehicles, carrier and coating materials were 
used toformulate these drug delivery systems. 
Principle of Liquisolid Compacts: 
Important terminologies in Principle: 
Liquid medication includes liquid lipophilic drugs and 
drug suspensions or solutions of solid water insoluble 
drugs in suitable non-volatile solvent systems.  
Liquisolid system refers to powdered forms of liquid 
medications formulated by converting liquid lipophilic 
drugs, or drug suspensions or solutions of water insoluble 
solid drugs in suitable non-volatile solvent systems, into 
dry, nonadherent, free-flowing and readily compressible 
powder admixtures by blending with selected carrier and 
coating materials.  
Carrier material refers to a preferably porous material 
possessing sufficient absorption properties, such as 
microcrystalline and amorphous cellulose, which 
contributes in liquid absorption.  
Coating material refers to a material possessing fine and 
highly adsorptive particles, such as various types of silica, 
which contributes in covering the wet carrier particles and 
displaying a dry looking powder by adsorbing any excess 
liquid.
15
 
With the liquisolid technology, a liquid may be 
transformed into a free flowing, readily compressible and 
apparently dry powder by simple physical blending with 
selected excipients named the carrier and coating material. 
The liquid portion, which can be a liquid drug, a drug 
suspension or a drug solution in suitable non-volatile 
liquid vehicles, is incorporated into the porous carrier 
material (Fig. 1).  
 
Figure 1: Schematic representation of liquisolid systems. 
Inert, preferably water-miscible organic solvent systems 
with high boiling point such as propylene glycol, liquid 
polyethylene glycols, or glycerine are best suitable as 
liquid vehicles. Once the carrier is saturated with liquid, a 
liquid layer is formed on the particle surface which is 
instantly adsorbed by the fine coating particles. Thus, an 
apparently dry, free flowing, and compressible powder is 
obtained. Usually, microcrystalline cellulose is used as 
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carrier material and amorphous silicon dioxide (colloidal 
silica) as coating material.  
Preparation of liquid solid compacts: 
As shown in figure, a liquid lipophilic 
drug(e.g.Chlorpheniramine, Clofibrate, etc.) can be 
convertedinto a liqui-solid system without being further 
modified. Onthe other hand, if a solid water-insoluble drug 
(e.g.Hydrochlorothiazide, Prednisone, etc.) is formulated, 
itshould be initially dissolved or suspended in a suitable 
nonvolatilesolvent system to produce a drug solution or 
drugsuspension of desired concentration. Next, a certain 
amount of the prepared drug solution orsuspension, or the 
liquid drug itself, is incorporated into aspecific quantity of 
carrier material which should bepreferably of a porous 
nature and possessing sufficientabsorption properties, such 
as powder and granular grades ofmicrocrystalline and 
amorphous cellulose are most preferredas carriers. The 
resulting wet mixture is then converted intoa dry-looking, 
non adherent, free-flowing and readilycompressible 
powder by the simple addition and mixing of acalculated 
amount of coating material. Excipients possessingfine and 
highly adsorptive particles, such as various types 
ofamorphous silicon dioxide (silica), are most suitable for 
thisstep. Before compression or encapsulation, 
variousadjuvants such as lubricants and disintegrates 
(immediate)or binders (sustained-release) may be mixed 
with thefinished liqui-solid systems to produce liqui-solid 
compactsi.e. tablets or capsules.
16, 17, 18 
 
Figure 2: Schematic outline of the steps involved in the 
preparation of liquisolid compacts 
Pre-compressionevaluation parameters of liquid solid 
systems: 
Flow Properties of the Liqui-Solid System:
19, 20
 
The flow properties of the liqui-solid systems 
wereestimatedby determining the angle of repose, 
Carr’sindex, andHausner’s ratio.The angle of reposewas 
measured by thefixed funnel and freestanding conemethod. 
The Bulk densityand Tap densities were determined for the 
calculation ofHausner’s ratio andCarr’s Index. 
Angle of repose: 
The angle of repose physical mixtures of liqui-
solidcompacts were determined by fixed funnel method. 
Theaccurately weighed physical mixtures of liqui-
solidcompacts were taken in a funnel. The height of the 
funnelwas adjusted in such a way that the tip of the funnel 
justtouches the apex of the heap of the powder. The 
powder wasallowed to flow through the funnel freely into 
the surface.The height and diameter of the powder cone 
was measuredand angle of repose was calculated. 
Tan θ= h/r 
Where, θ is the angle of repose, h is the height in cms,r is 
the radius in cms 
Values for angle of repose ≤ 300 usually indicate a 
freeflowing material and angles ≥ 400 suggest a poorly 
flowingmaterial. 25- 30 showing excellent flow 
properties,31-35showing good flow properties, 36-40 
showing fair flowproperties, 41-45 showing passable flow 
properties. 
Bulk Density: 
The loose bulk density and tapped density were 
determinedby using bulk density apparatus. Apparent bulk 
density wasdetermined by pouring the blend into a 
graduated cylinder.The bulk volume (Vb) and weight of 
the powder (M) wasdetermined. The bulk density was 
calculated using theformula: 
Db=M/Vb 
where, M is the mass of powder, Vb is bulk volume of 
powder 
Tapped Density: 
The measuring cylinder containing a known mass of 
blendwas tapped for a fixed time. The minimum volume 
(Vt)occupied in the cylinder and the weight (M) of the 
blendwas measured. The tapped density was calculated 
using theformula: 
Dt= M/Vt 
Where, M is the mass of powder, Vt is tapped volume of 
powder 
Carr’s Index (%): 
The compressibility index has been proposed as an 
indirectmeasure of bulk density, size and shape, surface 
area,moisture content and cohesiveness of material 
because all ofthese ca influence the observed 
compressibility index.The simplest way for measurement 
of free flow of powder isCarr’s Index, a indication of the 
ease with which a materialcan be induced to flow is given 
by Carr’s index (CI) whichis calculated as follows: 
CI (%) = [(Tapped density – Bulk density) / 
Tappeddensity] x 100 
The value below 15% indicates a powder with usually 
givesrise to good flow characteristics, where as above 
25%indicates poor flowability. 1-10 showing excellent 
flowproperties, 11-25 showing good flow properties 16-
20showing fair to passable, 21-25 showing passable. 
Hausner’s Ratio: 
Hausner’s ratio is an indirect index of ease of powder 
flow.It is calculated by the following formula. 
Hausner’s Ratio=Tapped density (ρt) / Bulk density (ρb ) 
Where ρt is tapped density and ρb is bulk density. 
LowerHausner’s ratio (<1.25) indicates better flow 
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properties thanhigher ones, between 1.25 to 1.5 showing 
moderate flowproperties and more than 1.5 poor flow. 
Fourier Transform Infra Red Spectroscopy (FT-IR): 
FT-IR spectra of prepared melt granules are recorded on 
FTIR-8400 spectrophotometer. Potassium bromide (KBr) 
pellet method is employed and background spectrum is 
collected under identical situation. Each spectrum is 
derived from single average scans collected in the region 
400 - 4000cm-1 at spectral resolution of 2cm-2 and ratio 
against background interfereogram. Spectra are analyzed 
by software.
21
 
Differential scanning calorimetry (DSC): 
Differential scanning calorimetry (DSC) is performed in 
order to assess the thermotropic properties and the thermal 
behaviors of the drug, excipients used in the formulation of 
the liquisolid system. Complete disappearance of 
characteristic peaks of drug indicates the formation of drug 
solution in the liquisolid powdered system, i.e., the drug is 
molecularly dispersed within the liquisolid matrix.
21, 22, 23
 
X-ray diffraction (XRD): 
For the characterization of crystalline state, X-ray 
diffraction (XRD) patterns are determined for physical 
mixture of drug and excipients used in formulation and for 
the prepared liquisolid compacts.
24
 Absence of 
constructive specific peaks of the drug in the liquisolid 
compacts in X-ray diffractogram specify that drug has 
almost entirely converted from crystalline to amorphous or 
solubilized form. Such lack of crystallinity in the liquisolid 
system was understood to be as a result of drug 
solubilization in the liquid vehicle i.e., the drug has formed 
a solid solution within the carrier matrix. This 
amorphization or solubilization of drug in the liquisolid 
compacts it may contribute to the consequent improvement 
in the apparent solubility and enhancement of dissolution 
rate of the drug.
25
 
Post compression evaluation parameter of liquid solid 
compacts: 
Weight Variation: 
Twenty tablets were randomly selected from each batch 
andindividually weighed. The average weight and 
standarddeviation three batches were calculated. It passes 
the test forweight variation test if not more than two of the 
individualtablet weights deviate from the average weight 
by more thanthe allowed percentage deviation and none 
deviate by morethan twice the percentage shown. It was 
calculated on anelectronic weighing balance. 
Thickness: 
The thickness of liqui-solid tablets was determined by 
usingDigital micrometer. Ten individual tablets from each 
batchwere used and the results averaged. 
Hardness: 
The hardness of the tablets was determined by 
usingMonsanto hardness tester. Five individual tablets 
from eachbatch were and results averaged. 
Friability: 
The friability values of the tablets were determined using 
aRoche-type friabilator. Accurately weighed six tablets 
wereplaced in Roche friabilator and rotated at 25 rpm for 4 
min.Percentage friability was calculated using the 
followingequation. 
Friability = ([WO – W] /WO) x100 
Where, 
WO = Weight of the tablet at time zero before revolution, 
W = Weight of the tablet after 100 revolutions. 
Disintegration Test 
Six tablets were taken randomly from each batch and 
placedin USP disintegration apparatus baskets Apparatus 
was runfor 10 minutes and the basket was lift from the 
fluid,observe whether all of the tablets have disintegrated. 
Contact angle measurement: 
For assessment of wettability, contact angle of liquisolid 
tablets is measured according to the imaging method. The 
commonly used method is to measure contact angle 
directly for a drop of liquid resting on a plane surface of 
the solid, the so-called imaging method. A saturated 
solution of the drug in dissolution media is prepared and a 
drop of this solution is put on the surface of tablets. The 
contact angles are calculated by measuring the height and 
diameter of sphere drop on the tablet.
24
 
Scanning electron microscopy (SEM): 
Scanning electron microscopy (SEM) is utilized to assess 
the morphological characteristics of the raw materials and 
the drug-carrier systems.
25
 
In-vitro dissolution studies: 
Works of many researchers revealed that technique of 
liquisolid compacts could be a promising alternative for 
formulation of water-insoluble drugs. This technique of 
liquisolid compacts has been successfully employed to 
improve the in-vitro release of poorly water soluble drugs 
as hydrocortisone, 
26
Prednisolone 
27
Carbamazepine 
28
Piroxicam
24, 29
Also several water insoluble drugs 
nifedipine, gemfibrozil, and ibuprofen, have shown higher 
bioavailability in rats as compared to their commercial 
counterparts. 
9. In-vivo evaluation of liquisolid systems: 
This liquisolid technology is a promising tool for the 
enhancement of drug release of poorly soluble drugs. The 
absorption characteristics of Hydroclorothiazideliquisolid 
compacts in comparison with commercial tablets were 
studied in beagle dogs. Significant differences in the area 
under the plasma concentration-time curve, the peak 
plasma concentration and the absolute bioavailability of 
the liquisolid and the commercial tablets were observed. 
However, for the mean residence time, the mean 
absorption time, and the rate of absorption no significant 
differences were found. The absolute bioavailability of the 
drug from liquisolid compacts was 15% higher than that 
from the commercial formulation.
30
 
Stability studies: 
Drug content was determined after the crystals were 
charged for accelerated stability studies according to ICH 
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guidelines. Samples were taken and analysed for specified 
intervals.  
Bioavailability assessment for different active 
pharmaceutical ingredients: 
Bioavailability assessment is required for 
liquisolidtechnique. Because it was proved that enhancing 
the drugreleases from the dosage form by determination of 
in-vitrorelease studies. So, this parameter should establish 
fordetermination of the efficacy of the formulation.
30 
Atorvastatin calcium (ATR) is a BCS class II drug used as 
alipid lowering agent by acting as 
HMGCoAreductaseinhibitor. The prepared liquisolid 
compacts of ATR showedhigher release rates compared to 
the directly compressedtablets. The pharmacokinetic 
parameters of liquisolidcompacts of ATR, such as the 
AUC, tmax and Cmax showedthe better bioavailability 
compared with the conventionalformulation.
31
 
Liquisolid Compacts of Aceclofenacorodispersible tablets 
were formulation and evaluated. The study is based on the 
effect of combined mixture of super disintegrants 
disintegrating action on drug release. Propylene glycol, 
PEG 400, Tween 80, microcrystalline cellulose were used 
as carrier. The liquisolid compacts with Sodium starch 
glycolate added intra granularly and Crosspovidone extra 
granularly showed highest dissolution rate. 
Orodispersibleliquisolid compacts prepared with Tween 80 
enhance the dissolution rate of aceclofenac to a larger 
extent.
32 
Approaches to augment dissolution of active 
pharmaceutical ingredient release from its immediate 
release tablets: 
Liquisolid compacts confirmed significantly higher 
drugrelease rates, in different dissolution media, compared 
totablets prepared by the direct compression method. It 
wasalso observed that the drug dissolution rate from 
liquisolidtablets were independent of the volume of 
dissolutionmedium, in difference to the plain tablets which 
exposedeclining drug release patterns with decreasing 
dissolutionvolumes.
27
 
Cyclosporine (CS) Self Micro-Emulsifying Tablet 
(SME),the tablets were prepared by the liquisolid 
compactiontechnique. Formulation consists of oil, 
surfactant and cosurfactantwhich were selected on the 
basis of solubility andemulsification ability for the SME 
formulation. In this study,the mixture of Lauroglycol FCC: 
Maisine 35-1 (1: 1w/w)was selected as the oil phase, PEG-
35 Castor Oil wasselected as the surfactant and PEG-400 
was selected as theco-surfactant. 1 to 6 was selected as the 
ratio between thedrug and the mixture. An Emulsion could 
not be formed inseveral oils, such as Carpryol 90, 
Lauroglyol 90 andLauroglycol FCC even in which the CS 
has good solubility.Due to the cyclic structure of CS-A, 
some excipientsabsorbed the drug and could not be 
selected as carriermaterial and coating material, e.g., silica 
powders. Theliquisolid tablets were effective in enhancing 
dissolution ofCS-A, a poorly water-soluble drug. The 
tablets exhibitedgood flowability and compactability. The 
results showed thatthe liquisolid compaction technique is a 
promising alternativetechnique to improve the solubility 
and the dissolution rate,for poorly water-soluble drugs CS-
A.
33
 
Naproxen is a non-steroidal anti-inflammatory drug 
(NSAID)commonly used for the reduction of fever, pain 
andinflammation. Liquisolid compacts change the 
properties ofnaproxen particles by simply dispersing the 
drug particles ina non-volatile hydrophilic liquid vehicle, 
which increase thewetting properties of drug particles, and 
enhances thedissolution rate and shows improved 
bioavailability of thedrug. At present, naproxen is 
available commercially in high 
dose tablets between 250 and 500 mg; the 
liquisolidformulations may help in reduction of the dose 
also.
34
 
CONCLUSION: 
This technique is a potential substitute for formulation of 
water-insoluble/soluble drugs. The improved rate of drug 
dissolution from liquisolid tablets is almost certainly due 
to an amplify in wetting properties and surface area of 
drug particles obtainable for dissolution. Rapid 
disintegration ratesare experimentally compared to 
conventional tablets. Hence they show improved release 
rates and greater bioavailability. By this technique, 
sustained drug delivery systems were also be developed 
for the water soluble drugs in which hydrophobic non-
volatile solvents are used as vehicles Alteration of 
formulation by use of definite agent’s source it control the 
release of drugs from the liquisolid tablets.
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